By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The Life Science Nation (LSN) team is gearing up for the highly anticipated RESI Boston conference, set to take place from September 25-27, 2024, at the Westin Copley Place Hotel. This event promises to be a cornerstone for early-stage life science and healthcare investment, offering attendees knowledge through a curated program of 7 insightful investor panels.
RESI Boston will kick off with an in-person event on September 25, providing face-to-face networking and engagement opportunities. The conference will then continue with virtual partnering sessions on September 26-27, allowing participants to extend their interactions and explore new opportunities from anywhere in the world.
The event will bring together a diverse lineup of panelists from various investment groups, each specializing in critical sectors such as Partnering with Pharma, Angel Investors, Digital Health, Early-stage Therapeutics, Diagnostics, Family Offices, and AI in Healthcare. These industry leaders will offer their unique perspectives on investment strategies, emerging industry trends, and the evolving startup ecosystem.
At the heart of RESI Boston is the goal of fostering meaningful dialogue between investors and fundraising CEOs. The panels are designed to provide actionable insights on capital-raising strategies and partnership acquisition, equipping companies with the tools they need to navigate the complex fundraising landscape successfully. For founders and CEOs, these panels represent an invaluable opportunity to connect directly with investors, broaden their networks, and gain the critical insights needed to drive their businesses forward.
Join these panelists at RESI Boston:
 John Abeles General Partner Northlea Partners |
 Wayne Boulais Co-Founder & Partner Tensility Venture Partners |
 Nat Brinn Partner VC23 |
 Carter Caldwell Program Director, Penn Medicine Co-Investment Program Penn Center for Innovation (PCI) |
 Ian Chiang Partner Flare Capital Partners |
 Bruce Cohen Venture Partner Xeraya Capital |
 Fabrizio Conicella Head COI&C, Center of Open Innovation & Competence Chiesi |
 Neel Desai Executive Director, BD & Licensing Biogen |
 Ronald Dorenbos VP, Business Development Evotec |
 David Fogel Angel Investor Mass Medical Angels |
 Chris Garabedian CEO Xontogeny |
 Allan Gobbs Managing Partner ATEM Capital |
 Jill Goldstein Senior Associate Vida Ventures |
 Shahram Hejazi Partner BioAdvance |
 Deborah Hemingway Managing Partner Ecphora Capital |
 Tomoko Ishikura Partner Kicker Ventures |
 Jun Jeon Principal Khosla Ventures |
 Priyanka Kanal Associate McKesson Ventures |
 Kristin King-Jankiewicz Member & Head of Group Management Boston Harbor Angels |
 Michael Langer Founder & Managing Partner T.Rx Capital |
 Claire Leurent Managing Director AbbVie Ventures |
 Fiona Mack VP, Head Co.Lab Cambridge US Bayer |
 Hannah Mamuszka Managing Partner 10Edison Capital |
 Andrew Merken Sharholder Polsinelli PC |
 James Murray Partner ExSight Ventures |
 Gauri Nair Senior Director Business Development AbCellera |
 Soyoung Park General Partner 804 Venture Partners |
 John Parker Founder and Managing Director Springhood Ventures |
 John Pennett Angel Investor Mid Atlantic Bio Angels |
 Garrett Peterson Chief Revenue Officer Yahara Ventures |
 David Prim Senior Associate Broadview Ventures |
 Asli Sahin Director, Search & Evaluation, Neuroscience AbbVie |
 Squire Servance Founder & Managing Partner Syridex Bio |
 Sunil Shah CEO o2h Ventures |
 Michka Sharpe Senior Associate BrightEdge |
 Elia Stupka Managing Director (Rome/Singapore) Angelini Ventures |
 Ashim Subedee Director, Catalyst Office Biomedical Advanced R&D Authority (BARDA) |
 Mike Thomas Managing Partner Bold Brain Capital |
 Joshi Venugopal Head of Region Europe, SVP Novartis |
Next Phase Newsletter 
Leave a comment